| 000 | 01403 am a22001813u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 245 | 0 | 0 | _aAn update on the use of inositols in preventing Gestational Diabetes Mellitus (GDM) and Neural Tube Defects (NTDs) |
| 260 | _c2020-12-01. | ||
| 500 | _a/pmc/articles/PMC7614183/ | ||
| 500 | _a/pubmed/32966143 | ||
| 520 | _aINTRODUCTION: Obstetric history and maternal body composition and lifestyle may be associated with serious complications both for the mother, such as gestational diabetes mellitus (GDM), and for the fetus, including congenital malformations such as neural tube defects (NTDs). AREAS COVERED: In view of the recent knowledge, changes of nutritional and physical activity habits ameliorate glycemic control during pregnancy and in turn improve maternal and neonatal health outcomes. Recently, a series of small clinical and experimental studies indicated that supplementation with inositols, a family of insulin sensitizers, was associated with beneficial impact for both GDM and NTDs. EXPERT OPINION: Herein, we discuss the most significant scientific evidence supporting myo-inositol administration as a prophylaxis for the above-mentioned conditions. | ||
| 540 | _a | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nExpert Opin Drug Metab Toxicol | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1080/17425255.2020.1828344 _zConnect to this object online. |
| 999 |
_c503 _d503 |
||